JNCCN 360 - Bladder - Published Medical Literature

Editor:

Thomas Flaig, MD

Advertisement

Advertisement

Published Medical Literature

Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update

Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

After Surgery for Upper Urinary Tract Urothelial Carcinoma: Surveillance or Chemotherapy?

Potential Genomic Predictors of Outcomes in High-Grade T1 Bladder Cancer

DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

Early Results With Buparlisib in Treatment of Metastatic Urothelial Carcinoma

Testicular Tuberculosis: Case Study of Rare Complication of Urothelial Cancer Treatment

Perioperative Chemotherapy for High‐Risk Upper Tract Urothelial Carcinoma

Early Findings With Magnetic Resonance–Guided Radiotherapy for Bladder Cancer

Sections

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.